Formulary guidance and transparency from P&T to point of care


Reality Check on Multiple Myeloma

Market access for multiple myeloma treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 52% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In July 2019, the FDA gave accelerated approval to Karyopharm Therapeutics Inc.’s Xpovio (selinexor) in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody
  • Key Findings: Many different drugs to treat multiple myeloma are available. The choice and dose of drug therapy depend on many factors, including the stage of the cancer, the age of the patient, kidney function of the patient and if a stem cell transplant is planned

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.